Business
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities IND application expected to be filed in first half of 2027 to seek authorization for clinical study in patients with pancreatic cancer Poster presented at the American Association of Cancer Research Annual Meeting 2026 MIRAMAR, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a cl
About this update from Hcw Biologics Inc.
[{"type":"image","alt":"HCW Biologics Inc.","displaySize":"","headline":null,"caption":"HCW Biologics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/41c465fea041fccd686f09c17f724fb7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6KmwD3A_ctXK0d88uCG5hQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMA--/https://media.zenfs.com/en/globenewswire.com/41c465fea041fccd686f09c17f724fb7","width":300,"height":150}},"lazy":false},{"type":"text","content":"Its lead T-Cell Engager HCW11-018b is shown to penetrate into the tumor microenvironment with potent and antigen-specific anti-pancreatic cancer activities","length":155,"tagName":"p"},{"type":"text","content":"IND application expected to be filed in first half of 2027 to seek authorization for clinical study in patients with pancreatic cancer","length":134,"tagName":"p"},{"type":"text","content":"Poster presented at the American Association of Cancer Research Annual Meeting 2026","length":83,"tagName":"p"},{"type":"text","content":"MIRAMAR, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation announced today major development regarding its tetra-valent, second-generation T-Cell Engager Program (the “Big BiTE”) based on its TRBC platform technology, was presented at the poster session at the American Association of Cancer Research (“AACR”) Annual Meeting 2026, which took place from April 17 – 22, 2026 in San Diego, California.","length":617,"tagName":"p"},{"type":"text","content":"HCW11-018b, the lead candidate of the “Big BiTE” program, is a tetra-valent T-cell engager designed to enhance anti-tumor activities and tolerability to treat a wide spectrum of solid tumors. The Company’s preclinical data showed HCW11-018b could significantly shrink well-established tumors and prevent cancer metastasis in xenograft animal models with broad coverage for human solid tumor indications.","length":403,"tagName":"p"},{"type":"text","content":"The new data in the poster has revealed the mechanism of action that drives these results. HCW11-018b utilizes Cis-binding (or cis-interaction) to regulate immune cell reacti...